JP3439490B2 - 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法 - Google Patents

蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法

Info

Publication number
JP3439490B2
JP3439490B2 JP28113692A JP28113692A JP3439490B2 JP 3439490 B2 JP3439490 B2 JP 3439490B2 JP 28113692 A JP28113692 A JP 28113692A JP 28113692 A JP28113692 A JP 28113692A JP 3439490 B2 JP3439490 B2 JP 3439490B2
Authority
JP
Japan
Prior art keywords
ala
glu
leu
pro
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP28113692A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06107693A (ja
Inventor
完三 岩城
恒孝 太田
雅司 栗本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority to JP28113692A priority Critical patent/JP3439490B2/ja
Priority to TW082107913A priority patent/TW241268B/zh
Priority to US08/127,278 priority patent/US5498697A/en
Priority to KR1019930019832A priority patent/KR100294977B1/ko
Priority to DE69331368T priority patent/DE69331368T2/de
Priority to EP93307668A priority patent/EP0594311B1/en
Publication of JPH06107693A publication Critical patent/JPH06107693A/ja
Priority to US08/555,860 priority patent/US5585474A/en
Priority to US08/827,864 priority patent/US5827691A/en
Application granted granted Critical
Publication of JP3439490B2 publication Critical patent/JP3439490B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP28113692A 1992-09-28 1992-09-28 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法 Expired - Fee Related JP3439490B2 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP28113692A JP3439490B2 (ja) 1992-09-28 1992-09-28 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
TW082107913A TW241268B (enExample) 1992-09-28 1993-09-25
KR1019930019832A KR100294977B1 (ko) 1992-09-28 1993-09-27 단백질과이단백질을코우드하는dna및이단백질의제조방법
US08/127,278 US5498697A (en) 1992-09-28 1993-09-27 Protein possessing metastasis-inhibitory activity
DE69331368T DE69331368T2 (de) 1992-09-28 1993-09-28 Herstellung und Benützung eines Metastasehemmendes Proteines.
EP93307668A EP0594311B1 (en) 1992-09-28 1993-09-28 Process for preparing a metastasis-inhibiting protein and uses thereof.
US08/555,860 US5585474A (en) 1992-09-28 1995-11-13 DNA encoding protein possessing metastasis-inhibitory activity
US08/827,864 US5827691A (en) 1992-09-28 1997-04-09 Process for preparing a protein which inhibits metastasis of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28113692A JP3439490B2 (ja) 1992-09-28 1992-09-28 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法

Publications (2)

Publication Number Publication Date
JPH06107693A JPH06107693A (ja) 1994-04-19
JP3439490B2 true JP3439490B2 (ja) 2003-08-25

Family

ID=17634871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP28113692A Expired - Fee Related JP3439490B2 (ja) 1992-09-28 1992-09-28 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法

Country Status (6)

Country Link
US (3) US5498697A (enExample)
EP (1) EP0594311B1 (enExample)
JP (1) JP3439490B2 (enExample)
KR (1) KR100294977B1 (enExample)
DE (1) DE69331368T2 (enExample)
TW (1) TW241268B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0981369B1 (en) 1997-05-12 2004-11-17 Aphton Corporation Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
US20030091574A1 (en) 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US6387661B1 (en) * 2001-03-23 2002-05-14 Pe Corporation (Ny) Nucleic acid molecules encoding human aminoacylase proteins
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN111050789A (zh) 2017-06-15 2020-04-21 癌症进展有限公司 用于诱导针对肿瘤和癌症的体液免疫和细胞免疫的组合物和方法
CN111704658B (zh) * 2018-06-11 2021-11-16 北京市农林科学院 具有消脂护肝功能的毛木耳糖肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925332A (ja) * 1982-08-04 1984-02-09 Mochida Pharmaceut Co Ltd 抗腫瘍性糖蛋白質の製法
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
JP2926409B2 (ja) * 1989-05-22 1999-07-28 株式会社林原生物化学研究所 癌転移抑制因子の製造方法

Also Published As

Publication number Publication date
EP0594311A1 (en) 1994-04-27
DE69331368T2 (de) 2002-08-08
KR940007056A (ko) 1994-04-26
KR100294977B1 (ko) 2001-09-17
DE69331368D1 (de) 2002-01-31
US5498697A (en) 1996-03-12
TW241268B (enExample) 1995-02-21
JPH06107693A (ja) 1994-04-19
EP0594311B1 (en) 2001-12-19
US5827691A (en) 1998-10-27
US5585474A (en) 1996-12-17

Similar Documents

Publication Publication Date Title
Segal et al. Stimulated neutrophils from patients with autosomal recessive chronic granulomatous disease fail to phosphorylate a M r-44,000 protein
PT99118B (pt) Processo de preparacao de protease de interleucina 1b,de inibidores da protease de interleucina 1b e de composicoes farmaceuticas
EA005581B1 (ru) ПОЛИПЕПТИДЫ ЦИТОКИНА Zcyto10 ЧЕЛОВЕКА И МЫШИ, КОДИРУЮЩИЕ ИХ ПОЛИНУКЛЕОТИДЫ И АНТИТЕЛА К УКАЗАННЫМ ПОЛИПЕПТИДАМ
JP3439490B2 (ja) 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
EP0437610A1 (en) Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide
JPH08508884A (ja) マクロファージ炎症蛋白変種
JPH05503512A (ja) 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
JPH04505753A (ja) 血小板活性化阻害ポリペプチドを製造する方法ならびにそれを用いた方法，組合せおよび組成物
EP1132402B1 (en) Peptide fragments having cell death inhibitory activity
CA2278596A1 (en) Novel human metallothionein
JPWO1998029446A1 (ja) サソリ由来神経ペプチド
KR100270348B1 (ko) 전사인자 에이피알에프
US5824551A (en) Method for modulating cell apoptosis
JP2863265B2 (ja) インターロイキン１インヒビター
JP3030386B2 (ja) 抗ガン剤
AU2003244571A1 (en) Cytomodulating Lipophilic Peptides for Modulating Immune System Activity and Inhibiting Inflammation
EP0412105A1 (en) Stem cell inhibitors
KR930000187B1 (ko) Dna 재조합 기술에 의해 제조된 생리적 활성물질의 안정화 방법 및 상기 물질을 함유하는 안정화 수용액 또는 분말의 제조방법
Sarfati et al. T-cell-derived IgE-binding factors. II. Purification and characterization of IgE-binding factors produced by human T cell leukemia/lymphoma virus-1-transformed T lymphocytes.
DK172400B1 (da) Fremgangsmåde til fremstilling af renset minactivin, minactivinkodende DNA-molekyle, rekombinant DNA-molekyle, sammensmeltet gen, vært, reagent til lokalisering og definering af grænserne for tumorer i histologiske prøver, samt anvendelse af det rekombinante DNA-molekyle, minactivinet og peptider deraf
Paggi et al. Glucose utilization by tumor cells: a post-translational modification of mitochondrial hexokinase may play a regulatory role
PT655251E (pt) Composicao farmaceutica para a profilaxia e o tratamento de fracturas
EP0850319B1 (en) Method for modulating cell apoptosis
US5654167A (en) Antimicrobial proteins, compositions containing same and uses thereof
JPH04279598A (ja) 血清カルシウム降下因子

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees